BiotechTube
X-Bolt Orthopedics

X-Bolt Orthopedics

Dublin, Ireland· Est.
x-bolt.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6M

Overview

X-Bolt Orthopedics is a private, commercial-stage medical device company focused on revolutionizing fracture fixation through its proprietary expanding bolt technology. Its core product, the Pro-X1 Trochanteric Nail, has demonstrated a remarkably low cut-out rate in major randomized controlled trials (RCTs), including the largest-ever RCT in extracapsular hip fracture fixation. Led by founder and orthopedic surgeon Brian Thornes, the company leverages strong clinical evidence to drive commercialization through a global distributor network while expanding its pipeline into spinal and other orthopedic applications.

Orthopedic TraumaHip FracturesSpinal Surgery

Technology Platform

Proprietary expanding bolt implant technology designed for stronger, rotationally stable fixation in bone, aimed at preventing implant cut-out and failure.

Funding History

2
Total raised:$6M
Series A$4.8M
Seed$1.2M

Opportunities

The aging global population and high incidence of osteoporotic hip fractures create a large and growing addressable market.
Superior clinical data from large RCTs provides a powerful tool for market penetration, value-based pricing, and displacing the standard of care.
The expandable technology platform allows for logical extension into adjacent high-value markets like spinal and other trauma applications.

Risk Factors

Commercial success depends on overcoming surgeon inertia and changing long-established surgical techniques for hip fracture fixation.
The company faces competition from large, well-resourced medical device giants with extensive sales forces and broad portfolios.
As a private company, it may have limited financial resources to simultaneously scale commercial operations, manage a global supply chain, and fund R&D for its pipeline.

Competitive Landscape

X-Bolt competes in the orthopedic trauma implant market against major players like DePuy Synthes (Johnson & Johnson), Stryker, Zimmer Biomet, and Smith & Nephew, who offer traditional screws, nails, and plates. Its primary competitive advantage is clinical evidence suggesting superior outcomes in preventing cut-out. It also competes with other innovative niche players and startups focusing on improved fixation in osteoporotic bone. The spinal market entry would pit it against dominant players like Medtronic and NuVasive.

More companies in Regenerative Medicine →More companies in Ireland →